Avacta Group plc (LON: AVCT) is the topic of conversation when Dr Martin Hall, Head of Life Sciences from Hardman & Co joins DirectorsTalk. Martin firstly explains what ‘Affimers’ are,
Alastair Smith, Chief Executive of Avacta Group commented: “I am delighted to be entering into this therapeutic development partnership with LG Chem which is a strong validation of the potential
Avacta Group Plc (LON: AVCT) is a pre-clinical stage biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology. The significant
Avacta Plc (LON:AVCT) is a pre-clinical biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology, which continues to dominate the
Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology
Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology
Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology
Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology
Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology
Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a revolutionary alternative to the established antibody
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
